Buy Abbott: defensive compounder with recurring cash flow. Libre diabetes devices drive growth; 2025 guidance reaffirmed.

Abbott Laboratories ABT shares are trading at a discount to the Zacks Medical Products industry. Its trailing 12-month price-to-book value of 4.91X is significantly lower than the industry average of ...

Abbott (NYSE: ABT) recently reported its Q2 results, with revenues and earnings exceeding our expectations. The company reported revenue of $10.4 billion and earnings of $1.14 on a per-share and ...

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Abbott Laboratories (NYSE:ABT) has significantly outperformed the broader S&P 500 index this year, with its stock price rising 18% compared to the S&P 500’s 6% gain. This strong performance stems from ...

Abbott (NYSE: ABT) will report its Q2 2024 results on Thursday, July 18. We expect the company to post revenue of $10.3 billion and earnings of $1.10 on a per share and adjusted basis, broadly ...

A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing in Abbott Laboratories (NYSE: ABT). Abbott is a longtime leader in the ...